The newly-approved device requires only that patients swallow it in their doctor's office to achieve weight loss, according ...

FDA approves swallowable Allurion Gastric Balloon for weight loss in adults with obesity who failed prior lifestyle programs.

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of four ...

Add Yahoo as a preferred source to see more of our stories on Google. Allurion reported that US obesity rates affect over 100 million people. Credit: Monkey Business Images/Shutterstock.com. (Monkey ...

Allurion Technologies, Inc. (the "Company") (OTCID: ALUR), a pioneer in metabolically healthy weight loss, announced today that it has appealed the decision by the New York Stock Exchange (the "NYSE") ...

(RTTNews) - Allurion Technologies, Inc. (ALUR), reported its financial results for the first quarter of 2025 and presented new clinical data at the European Congress on Obesity or ECO in Malaga, Spain ...

The Company plans to submit the fourth and final module of the Pre-Market Approval application to the FDA. Topline data were announced from the AUDACITY trial evaluating the Allurion Gastric Balloon, ...

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical ...

Add Yahoo as a preferred source to see more of our stories on Google. As manufacturers ramp up for a GLP-1 legal battle and every food brand seems to be releasing new protein-packed products, medical ...

In the AUDACITY trial, 58% of patients using the Allurion Balloon achieved at least a 5% total body weight loss at 48 weeks. The Food and Drug Administration (FDA) has approved Allurion Gastric ...